Eris Lifesciences Limited Bombay S.E.

Equities

ERIS

INE406M01024

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:48 2024-04-24 am EDT 5-day change 1st Jan Change
870.4 INR -1.31% Intraday chart for Eris Lifesciences Limited +0.02% -4.41%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business MT
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion MT
Transcript : Eris Lifesciences Limited - Shareholder/Analyst Call
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million RE
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion. CI
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals MT
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited. CI
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026 CI
Transcript : Eris Lifesciences Limited, Q3 2024 Earnings Call, Feb 13, 2024
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion. CI
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns RE
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics CI
Indian shares set to open higher tracking Asian peers RE
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024 CI
Transcript : Eris Lifesciences Limited, Q2 2024 Earnings Call, Nov 08, 2023
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Eris Lifesciences Limited entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion. CI
Eris Lifesciences Limited Enters into Term Loan Agreement to Avail the Rupee Term Loan Facility from HDFC Bank Limited CI
Transcript : Eris Lifesciences Limited, Q1 2024 Earnings Call, Aug 07, 2023
Eris Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Eris Lifesciences Gains Dermatology Trademarks Acquired from Glenmark via Deal with Unit Eris Oaknet MT
Transcript : Eris Lifesciences Limited, Q4 2023 Earnings Call, May 17, 2023
Eris Lifesciences' Consolidated Profit Falls in Fiscal Q4 MT
Chart Eris Lifesciences Limited
More charts
Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
883 INR
Average target price
1,081 INR
Spread / Average Target
+22.38%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. ERIS Stock
  4. ERIS Stock
  5. News Eris Lifesciences Limited
  6. Eris Lifesciences' : Consolidated Profit Jumps 21% in Fiscal Q4